Occipital Nerve (C2) Stimulation in the Treatment of Fibromyalgia
A Randomized Controlled Pilot Study to Examine the Efficacy of Greater Occipital Nerve (C2) Stimulation in the Treatment of Fibromyalgia
The study is designed as a prospective, randomized, double-blind, single center study with a 6 month duration post permanent system implantation. Forty patients will be implanted.
During trial stimulation, patients will be randomized into one of two study arms for two weeks. Crossover will occur at the 2 week study visit to the opposite group. After completion of these two arms, every patient will subsequently complete participation in the third study arm.
After completion of the third arm, patients will be evaluated to determine if they are a positive responder responder. If so, the patient will have the option of obtaining the permanent implant.
調査の概要
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Antwerpen、ベルギー
- Universitair Ziekenhuis Antwerpen
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patients able to provide informed consent to participate in the study;
- Patient has had chronic widespread pain for at least 3 months in all 4 body quadrants;
- Patient has at least 11 out of 18 tender points based on the tender points examination;
- Patient has attempted "best" medical therapy and has tried and failed at least three documented medically supervised treatments (including, but not limited to drugs, physical therapy, acupuncture, etc.);
- Patient medication has remained stable for at least 4 weeks prior to baseline data collection;
- Psychological screening has been completed and the patient has been cleared by a psychologist as a suitable study candidate;
- Patient agrees not to add or increase medication throughout the randomization trial period of the study;
- Patient is willing to cooperate with the study requirements including compliance with the treatment regimen and completion of all office visits.
Exclusion Criteria:
- Patient has current evidence of any psychiatric disorder, as documented by the DSM-IV-TR criteria with psychotic characteristics, (e.g. bipolar disorder, major depressive disorder);
- Patient has been diagnosed with any disease mimicking the symptoms of the Fibromyalgia Syndrome (e.g. Epstein Barr, autoimmune diseases, etc.) that is not currently being treated or has not been stable for at least 6 months;
- Patient is currently in active menopause;
- Patient has been diagnosed with sleep apnea and is not currently involved in a treatment regime;
- Patient has a history of substance abuse or substance dependency in the past 6 months prior to baseline data collection;
- Patient currently participating in another clinical study;
- Patient with demand-type cardiac pacemakers, an infusion pump or any implantable neurostimulator device;
- Patient is likely to require an MRI evaluation in the future;
- Patient is not willing to maintain current medication regimen;
- Female candidates of child bearing potential who are pregnant (confirmed by positive urine/blood pregnancy test), not using adequate contraception as determined by the investigator, or nursing (lactating) a child.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Suprathreshold Stimulation
Patients will be stimulated at supra-sensory threshold levels for two weeks using occipital stimulation
|
Occipital Nerve Stimulation will be used in each study arm using the Eon Mini neuromodulation system
|
|
偽コンパレータ:minimal stimulation
Patients will be stimulated at minimal stimulation for two weeks using occipital stimulation
|
Occipital Nerve Stimulation will be used in each study arm using the Eon Mini neuromodulation system
|
|
アクティブコンパレータ:Subthreshold Stimulation
Patients will be stimulated at sub-sensory threshold stimulation for two weeks using occipital stimulation
|
Occipital Nerve Stimulation will be used in each study arm using the Eon Mini neuromodulation system
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Fibromyalgia Impact Questionnaire (FIQ)
時間枠:End of 6 week stimulation trial
|
The Fibromyalgia Impact Questionnaire (FIQ) is a self administered scale that was developed to measure fibromyalgia patient status, progress and outcomes. It measures the components of health that are most affected by fibromyalgia. The maximum score is 100 and a higher score indicates a greater impact of the syndrome on the person. The change in the Fibromyalgia Impact Questionnaire (FIQ) will be analyzed and reported. |
End of 6 week stimulation trial
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。